에서 실시간으로 운영 중이에요! 자세히 알아보기

Annexon

ANNX

시가총액 US$6.46억

3.41 USD

-0.19

5.28%

장 마감 시점 업데이트됨 10월 16일 PM 4:00 EDT

프리마켓

시간외 거래

3.41

0.00

0%

1일

-5.28%

5일

-15.17%

1개월

-13.23%

3개월

-42.11%

6개월

-46.13%

연초 이후

-27.29%

1년

7.57%

5년

-83.57%

10년

-80.8%

소개: Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.

직원 수: 92

건강관리 생명공학

뉴스

긍정적

중립

부정적

투자 심리 3개월

긍정적 16.7%

중립 83.3%

부정적 0%

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to six new non-executive employees under the terms of the 2022 Employment Inducement Award Plan.

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Annexon: Preserving Patient Function Is The Real Investment Opportunity

Annexon targets functional patient outcomes in geographic atrophy and Guillain-Barré syndrome, aiming for clinical differentiation via vision and physical recovery preservation. ANNX maintains a cash runway into 2028, supported by $209.2M in liquidity and a $200M Oxford Finance facility, but future financing remains a risk. The ARCHER II trial pivots to functional vision endpoints, with key readouts expected in Q4 2026 and potential market expansion if vision preservation is confirmed.

Annexon: Preserving Patient Function Is The Real Investment Opportunity

Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting

Oral Presentations Highlight Phase 2 Vision Protection and Enrollment of a Consistent Phase 3 Patient Population Well-Positioned to Replicate Phase 2 Vision Outcomes ARCHER II is the First Pivotal Trial Designed to Demonstrate Protection of Vision in Geographic Atrophy, with Month 15 Results Expected in the Fourth Quarter of 2026 BRISBANE, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced two oral presentations on vonaprument at The Retina Society 59th Annual Scientific Meeting being held September 23-26, 2026 in Los Angeles, California.

Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on September 12, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Annexon to Participate in Upcoming September Investor Conferences

BRISBANE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq., president & chief executive officer, will participate in fireside chats during the following September investor conferences:

Annexon to Participate in Upcoming September Investor Conferences

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to three new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on August 10, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Annexon, Inc. (ANNX) Q2 2026 Earnings Call Transcript

Annexon, Inc. (ANNX) Q2 2026 Earnings Call Transcript

Annexon, Inc. (ANNX) Q2 2026 Earnings Call Transcript

Annexon Q2 Earnings Call Highlights

Annexon NASDAQ: ANNX said it expanded its pivotal ARCHER II trial of vonaprument in geographic atrophy, adding an independent 24-month dual primary endpoint alongside the study's existing 15-month primary endpoint. The company said it remains confident in a planned fourth-quarter assessment of the 15-month endpoint while seeking to capture longer-term efficacy data for a potential product label.

Annexon Q2 Earnings Call Highlights

Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones

Rapid, Positive Clinical Outcomes in GBS FORWARD Study Reinforce Consistency and Reproducibility of Tanruprubart Treatment Effect Demonstrated in Phase 3 and Real-World Evidence Studies; BLA Submission Expected in Q4 2026

Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones

Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study

BRISBANE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced the addition of a Month 24 dual primary endpoint to complement the current Month 15 primary endpoint in its Phase 3 ARCHER II trial, and launch of an open-label extension (OLE) study of vonaprument for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy (GA). With a dual primary endpoint strategy, ARCHER II can achieve success in protecting against vision loss at either Month 15 or 24, which are independent efficacy timepoints.

Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study

뉴스 순위 보기

Lightweight Charts™를 사용해 가격 차트를 구현했어요.